We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-11.04%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$175M
AUM Growth
-$20.2M
Cap. Flow
+$10.1M
Cap. Flow %
5.76%
Top 10 Hldgs %
36.8%
Holding
85
New
16
Increased
25
Reduced
11
Closed
19

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$3.77M
2
VAR
Varian Medical Systems, Inc.
VAR
+$3.33M
3
BSX icon
Boston Scientific
BSX
+$3.08M
4
ELGX
Endologix Inc
ELGX
+$2.78M
5
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$2.76M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$5.61M
2
ALIM
Alimera Sciences
ALIM
+$4.5M
3
SPNC
Spectranetics Corp
SPNC
+$4.48M
4
COO icon
Cooper Companies
COO
+$4.42M
5
CPHD
Cepheid Inc
CPHD
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 65.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSI
51
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$751K 0.43%
+135,000
New +$996K
FOMX
52
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$748K 0.43%
+102,000
New +$1.04M
FEIC
53
DELISTED
FEI COMPANY
FEIC
$730K 0.42%
10,000
-5,000
-33% -$394K
DYAX
54
DELISTED
DYAX CORPORATION
DYAX
$449K 0.26%
23,500
+1,000
+4% +$23.9K
OCRX
55
DELISTED
Ocera Therapeutics, Inc.
OCRX
$414K 0.24%
131,000
+13,581
+12% +$52.3K
PTCT icon
56
CALL
PTC Therapeutics
PTCT
$6.15B
$401K 0.23%
15,000
– –
CBAY
57
DELISTED
Cymabay Therapeutics
CBAY
$388K 0.22%
200,000
– –
ALDX icon
58
Aldeyra Therapeutics
ALDX
$91.1M
$335K 0.19%
57,500
– –
DMK
59
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$312K 0.18%
1,150
– –
CPRX
60
DELISTED
Catalyst Pharmaceutical
CPRX
$300K 0.17%
100,129
-294,871
-75% -$1.27M
KALV
61
DELISTED
KalVista Pharmaceuticals
KALV
$286K 0.16%
5,714
+2,857
+100% +$244K
RCKT icon
62
Rocket Pharmaceuticals
RCKT
$382M
$252K 0.14%
+6,700
New +$308K
EVAR
63
DELISTED
Lombard Medical, Inc.
EVAR
$189K 0.11%
52,875
– –
SRPT icon
64
CALL
Sarepta Therapeutics
SRPT
$1.92B
$173K 0.1%
5,400
– –
ALIM
65
DELISTED
Alimera Sciences
ALIM
$100K 0.06%
3,014
-79,906
-96% -$4.5M
A icon
66
CALL
Agilent Technologies
A
$42.2B
– –
-100,000
Closed -$3.86M
ARAY icon
67
CALL
Accuray
ARAY
$34.6M
– –
-50,000
Closed -$319K
BIIB icon
68
Biogen
BIIB
$30.1B
– –
-9,250
Closed -$2.95M
COO icon
69
Cooper Companies
COO
$15B
– –
-100,000
Closed -$4.42M
ESPR
70
PUT
DELISTED
Esperion Therapeutics
ESPR
– –
-34,500
Closed -$2.14M
IRWD icon
71
Ironwood Pharmaceuticals
IRWD
$711M
– –
-119,400
Closed -$1.04M
PTCT icon
72
PUT
PTC Therapeutics
PTCT
$6.15B
– –
-60,000
Closed -$2.89M
STAA icon
73
STAAR Surgical
STAA
$1.24B
– –
-17,204
Closed -$151K
TMO icon
74
CALL
Thermo Fisher Scientific
TMO
$224B
– –
-37,500
Closed -$4.87M
SIEN
75
DELISTED
Sientra, Inc.
SIEN
– –
-24,140
Closed -$5.61M
1 2
3
4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2015 Portfolio in Review

As of Q3 2015, Pura Vida Investments held 85 positions worth $175M, down 10% from $195M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $10.1M of net new capital in Q3 2015, opening 16 new positions and adding to 25 existing holdings. Its largest new stake was Abbott: 80,000 shares worth $3.22M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 70% a quarter earlier.

On the sell side, the largest reduction was Alimera Sciences, an estimated $4.5M trimmed.

  • Pura Vida Investments's largest Q3 2015 buy was Abbott: 80,000 shares worth $3.22M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2015, an estimated $3.08M increase.
  • Pura Vida Investments's biggest Q3 2015 reduction was Alimera Sciences, cutting an estimated $4.5M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2015, selling an estimated $5.61M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $175M portfolio in Q3 2015.
  • Pura Vida Investments opened 16 new positions and closed 19 in Q3 2015.
  • Pura Vida Investments's portfolio value fell 10% quarter-over-quarter to $175M.

Based on Pura Vida Investments's 13F filing for Q3 2015, filed 16 Nov 2015.